Post Reply
4401-4420 of 4854
There's a brokerage house that cover best world with a buy just before short seller report come out.. so they are not god but rather we make them to be god since retailers tend to jeep when they saw brokerage houses giving buy call.. as a matter of fact, the reason why the brokerage house has an edge over retailers is due to their connections and ability to have 1st hand news.. in terms of analysis, retailers can actually be better than the analysts.. i think quite a few long term investors here had jeeped in during q1 or earlier last year, where medtecs price is 20+ cents and below.. if the analysts are so good, where are they at that time? As a matter of fact, they didn't expect medtecs to have a record profits and judging by trend, coming full year 2020 results would show medtecs results to be more than 100 times profit increase versus 2019
FrancisLim ( Date: 01-Feb-2021 10:33) Posted:
|
Talking about Covid19 stats.. using Worldometer to look at the number of cases worldwide:
On 15th March 2020,
Active cases (need treatment or hospitalised) 132,038
In June , Active cases 3,281,821
In Sept, Active cases 7,159,634
In Dec, Active cases 19,746,434
Today Feb 2021, Active cases 26,155,970
I believe in certain countries, the numbers are unreported hence could be lot higher.
Covid Active cases are increasing at exponential rates over the last 4 to 5 months starting around end Oct 2020 thereabout.
The use of PPE and gloves etc will increase with more active cases as more ppl will be hospitalised and require Covid treatment.
Increasing Covid tests and immunisation program around the world will also create more PPE demands. This is all open info and not rocket science..
Glove and medical companies will continue to cater to big demands for a while as guided by CEO.
Last update on strong demands was reported by glove company, Supermax.
Dyodd.
Luzern ( Date: 01-Feb-2021 10:10) Posted:
|
If we look at fundamentals, ask yourself why the 2 broking houses quoted by one of our the forum poster, put Medtecs on Restricted list?
If a company only talk, and no action, we have to be careful. The broking houses putting the stock on restricted list is a sign. The nextinsight article also spoke rosily of Best World before it was suspended.
DYODD
If a company only talk, and no action, we have to be careful. The broking houses putting the stock on restricted list is a sign. The nextinsight article also spoke rosily of Best World before it was suspended.
DYODD
nqing87 ( Date: 01-Feb-2021 10:08) Posted:
|
All SG Blue Chips in the RED for the last 3 days. Jialat Leow. Hope Medtecs is the Great Saviour. huat arh
Agree. I am not selling but buying. Let us Huat together !!!! CNY coming , Huat Arh
Longtermer ( Date: 01-Feb-2021 10:06) Posted:
| ||||||||||||||||||||||||||
More Than 98.3 Million Shots
Given: Covid-19 Tracker
The U.S. has administered 31.8 million doses vaccine campaign goes global
Updated: February 1, 2021, 9:05 AM GMT+8
The latest rate was roughly 4.20 million doses a day, on average.
https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/
I think those who are looking at fundamental perspective probably are not looking at share buyback.. in fact we shouldn't be anticipating so much on mainboard listing also cos for me personally, I'm more interested in simply whether the company can provide sustainable profits in years to come.. but I think u are the one who keep harping on share buyback as if the company cannot survive the onslaught without doing it
FrancisLim ( Date: 01-Feb-2021 09:28) Posted:
|
Guys, Repost this article for all since the previous thread was removed.
The results coming in a couple of weeks time and lets hold tight our shares.
Dun contra. Dun buy if ok But dun sell.
If needed to sell, dun sell cheap. Lets huat together!
MEDTECS: 4Q2020 profit to be record, is stock ready for re-rating?
Written by Leong Chan Teik
Published: 21 January 2021
It doesn' t help that DBS is the only one providing coverage, so Medtecs needs time to gain more significant traction among Singapore investors.
Being the only listed PPE producer in Singapore has added to that challenge as has the fact that Medtecs has been virtually non-existent on the radar of Singapore investors pre-Covid.
Its 4Q2020 results, likely to be announced in weeks to come, could lend a sparkle to the market' s view.
Greater positivity could materialise if Medtecs will once again provide guidance on its revenue and profit for the near term.
More critically, Medtecs will need to highlight that its business fundamentals have been strengthened for good by Covid-19.
DBS' 21-page initiation report did delve into that, as the following excerpts show:
MED has been a long-time supplier for customers such as Premier Inc. and the governments of Taiwan and Singapore. We believe this relationship bodes well for the Group, enabling MED to remain a choice supplier even after COVID-19. The Group had sacrificed higher sales of Medtecs branded products to meet the needs of these customers during COVID-19.
47% of 9M20 manufacturing revenue was attributed to previous customers, translating to an estimated c.150% rise in sales generated from these groups of customers. Additionally, we believe there is a level of stickiness in the relationship between MED and its larger customers who may be resistant to seeking alternative PPE producers given the need for quality assessments.
MED has been careful not to layout large sums on capital expenditure as the Group is aware of the unsustainable nature of current demand. Most of MED&rsquo s output has been met by increasing round-the-clock shift workers, converting idle plants into additional production bases and boosting efficiency.
Going forward, we believe MED will study the viability of establishing new manufacturing bases with a possible focus on Europe. Some countries may turn inward to domestic producers for important medical supplies and MED may expand accordingly to meet these needs.
MED&rsquo s transition away from an original design manufacturing (ODM) business model is expected to be a key driving factor behind MED&rsquo s larger earnings post-COVID. We estimate that ASPs generated from the sales of own branded products could be over double that of sales of non-branded products.
As such, while PPE product ASPs in the market are expected to normalise in future, ASPs recorded by MED&rsquo s, while lower than in FY20, are estimated to still remain c.90% higher compared to the preCOVID period.
Our base case estimates put post-COVID demand for gowns and masks at c.25% and c.5% of demand during pandemic levels, driven by international stockpiling of PPE. We believe that COVID-19 has heightened the awareness and importance of PPE stockpiling and expect most countries that MED serves to stockpile a reasonable 90 days of PPE, creating medium-term demand for gowns and masks after COVID-19.
Notably, MED&rsquo s customers are largely from high income nations such as the UK, Germany and the US which we think possess the capability to stockpile. In the longer-term, expiring PPE products may give a permanent boost to PPE demand as governments replenish their stockpiles of PPE.
The results coming in a couple of weeks time and lets hold tight our shares.
Dun contra. Dun buy if ok But dun sell.
If needed to sell, dun sell cheap. Lets huat together!
MEDTECS: 4Q2020 profit to be record, is stock ready for re-rating?
Written by Leong Chan Teik
Published: 21 January 2021
| Medtecs International is the only Singapore-listed producer of personal protective equipment (PPE), a business that has been critical in the fight against Covid-19. As its factories in China, Cambodia and the Philippines ramp up production of PPE for global markets including Europe and the US, profits and cashflow have turned into an unprecedentedly large incoming tide for Medtecs. Based on its guidance in 3Q results announcement, Medtecs will record at least US$130 million in net profit for FY20. In comparison, it was just US$1.2 million in FY2019. See how the 2020 quarters add up:
Given the fast-evolving business environment in 2020, Medtecs gave its first guidance on 5 May 2020: It said it &ldquo expects revenue and profit growth in the second quarter to exceed that of 1Q 2020&rdquo . It proved to be an incredible understatement. 2Q20 profit turned out to be US$35 million, far exceeding the $3.7 million recorded in 1Q20. DBS Group, which is the only house covering Medtecs currently, has opted to be conservative about its 2020 forecast. In its initiation coverage on 8 Dec 2020, DBS forecasted US$130 million -- in other words, exactly the minimum based on Medtecs' 13 Oct 2020 guidance. This opens the door wide open for DBS to upgrade its target price after the actual higher profit is announced. Consider also the arguably low valuation of Medtecs. Based on the US$130 million profit forecast, which is 31.6 Singapore cents EPS, the stock' s PE ratio is 3.5X on a recent stock price of $1.12. Is the market overly worried about the sustainability of the exceptional business environment in 2020 for Medtecs? |
||||||||||||||||||||
It doesn' t help that DBS is the only one providing coverage, so Medtecs needs time to gain more significant traction among Singapore investors.
Being the only listed PPE producer in Singapore has added to that challenge as has the fact that Medtecs has been virtually non-existent on the radar of Singapore investors pre-Covid.
Its 4Q2020 results, likely to be announced in weeks to come, could lend a sparkle to the market' s view.
Greater positivity could materialise if Medtecs will once again provide guidance on its revenue and profit for the near term.
More critically, Medtecs will need to highlight that its business fundamentals have been strengthened for good by Covid-19.
DBS' 21-page initiation report did delve into that, as the following excerpts show:
| 1. Steady customer relationships a bedrock for Manufacturing segment. |
47% of 9M20 manufacturing revenue was attributed to previous customers, translating to an estimated c.150% rise in sales generated from these groups of customers. Additionally, we believe there is a level of stickiness in the relationship between MED and its larger customers who may be resistant to seeking alternative PPE producers given the need for quality assessments.
| 2. Post-pandemic strategy &ndash A curated approach. |
Going forward, we believe MED will study the viability of establishing new manufacturing bases with a possible focus on Europe. Some countries may turn inward to domestic producers for important medical supplies and MED may expand accordingly to meet these needs.
| 3. Transition away from ODM model to raise ASPs. |
As such, while PPE product ASPs in the market are expected to normalise in future, ASPs recorded by MED&rsquo s, while lower than in FY20, are estimated to still remain c.90% higher compared to the preCOVID period.
| 4. Main earnings driver: MED&rsquo s future earnings to be sustained by post-pandemic PPE stockpiling. |
Notably, MED&rsquo s customers are largely from high income nations such as the UK, Germany and the US which we think possess the capability to stockpile. In the longer-term, expiring PPE products may give a permanent boost to PPE demand as governments replenish their stockpiles of PPE.
thanks for the alert.. good to keep each other informed about this Cbank.. hope they sell to me at 100/101/102.. i am queuing.. last round managed to catch 102/103/104.. my 100/101 and partial 102 not filled..
sallylow ( Date: 01-Feb-2021 09:54) Posted:
|
volume very low...calm b4 the storm??? storm upwards hopefully.....DYODD
Be Careful cimb prop traders still selling this down. Bought some at 105 to test and it' s all them. Be careful they are still manipulating.
cbank traders really the worst breed
cbank traders really the worst breed
Bro, Why do you want Medtecs to do sharebuy back now?
I can see Medtecs green among the sea of reds..
Can tell us more??
FrancisLim ( Date: 01-Feb-2021 09:28) Posted:
|
Dont waste time with getting share buyback mandate and the hype.
nqing87 ( Date: 01-Feb-2021 09:27) Posted:
|
i think u have a misguided idea that with share buyback, it can remove the price suppression.. in real facts, share buyback or directors buying do not help much in moving up the share price especially in counters with high daily volume transaction and with shareholdings mainly in retailers.. company can throw money and buy 1mil shares everyday (which will exhaust their cash pool quickly in weeks), but believe me that price will still be around the same level.. the bb are very much stronger than anyone.. share buyback just brings in cheap comfort to retailers only.. as a fundamental investor, i look at company results and if it is not to my expectation, no matter how much share buyback perform or directors buying, i will not hold..
FrancisLim ( Date: 01-Feb-2021 09:17) Posted:
|
So far after getting share buyback mandate, any sare bought back by the co to lift the suppressed price?
NATO
NATO
Longtermer ( Date: 30-Jan-2021 14:18) Posted:
|
Did SJ remove the original MT thread for fear of this? 😆
Deepimpact ( Date: 30-Jan-2021 19:27) Posted:
|
All the reasons for this counter to go North! But but but....
ETLee8 ( Date: 31-Jan-2021 23:26) Posted:
|
Over the weekend, the whole world news from US to Europe to Asia, all are talking about MASKS.
Monday week all Masks stocks will cheong.
Mainboard, Share Buyback, Institutions Interests, Medstop Reddit & Finally Results will bring this Medtecs to all time hgh.
Monday week all Masks stocks will cheong.
Mainboard, Share Buyback, Institutions Interests, Medstop Reddit & Finally Results will bring this Medtecs to all time hgh.
Battle123 ( Date: 31-Jan-2021 23:07) Posted:
|
Currently whole world covid19 situations no good.
Some going for lock down
US mandatory to wear mask on public transport. I think they shld follow Spore wear mask once u out of your home.
Some going for lock down
US mandatory to wear mask on public transport. I think they shld follow Spore wear mask once u out of your home.
That might explain the big drop from 1.15 to 1.02
Shortsqueeze ( Date: 30-Jan-2021 20:56) Posted:
|